



Healing Outcomes and Cost Efficiency of Advanced Skin Substitutes for Diabetic Foot Ulcers Under the CMS Payment Framework

Article Record

Subramanian Gunasekaran^{§*}
PhD
*Corresponding Author



§ R&D, Encoll Corp., Fremont, United States

RECEIVED

2026-05-02

ACCEPTED

2026-05-11

ONLINE PUBLISHED

2026-05-28

PUBLISHED

2026-06-23

PEER REVIEW

Double Blind

Abstract

Background: Diabetic Foot Ulcers (DFUs) are associated with substantial morbidity, health care utilization, and risk of lower-extremity amputation. Advanced wound treatments such as skin substitutes are commonly used in the management of DFUs when standard wound care alone is insufficient. Recent changes in the Medicare Physician Fee Schedule (PFS) and the Outpatient Prospective Payment System (OPPS) have standardized reimbursement for skin substitutes based on surface area applied, increasing interest in healing outcomes and treatment-related costs under the CMS payment framework.

Objective: To descriptively compare published healing outcomes and estimated cost per healed DFU across selected advanced skin substitutes in the context of CMS payment policies.

Methods: A descriptive comparison was conducted using published DFU healing probabilities and estimated treatment-related costs for five advanced skin substitutes: Helicoll®, Grafix®, Apligraf®, Dermagraft®, and EpiFix®. Cost per healed DFU was calculated as the ratio of estimated treatment-related cost to reported healing probability. The primary effectiveness outcome was complete ulcer healing at 12 weeks. Cost assumptions were standardized using publicly available CMS reimbursement methodologies. No probabilistic modeling or ICER-based cost-utility modeling was conducted.

Results: Among the reported healing probabilities ranging from approximately 0.30 to 0.83 across products, Helicoll demonstrated a favorable balance of cost and effectiveness, with an annual per-patient cost of 20,000 and a reported wound closure rate of 0.83 in a 4-week clinical study with 4-week follow-up. This resulted in an estimated cost per healed DFU of approx. 24,000, which was substantially lower than comparator products. Estimated treatment-related costs varied substantially, resulting in wide variation in calculated cost per healed DFU. Helicoll has the higher reported healing probabilities and the lowest calculated cost per healed DFU among evaluated products.

Conclusion: In this comparative effectiveness analysis, Helicoll provided clinically meaningful healing outcomes at substantially lower cost compared with other specific advanced skin substitutes. These findings support Helicoll as a cost-effective treatment option for DFU management from a payer perspective and may inform reimbursement and formulary decision-making. This analysis provides a transparent cost-per-responder framework but does not constitute a formal cost-effectiveness model or systematic comparative effectiveness evaluation. Head-to-head trials and...

Full abstract continues on the metadata continuation sheet.

Diabetic Foot Ulcers

Skin Substitutes

Cost-Effectiveness

Helicoll

CMS Reimbursement

Wound Care Economics

Type I Collagen

AI USE STATEMENT

No generative AI was used for analysis or results.

FUNDING

This study was funded by Encoll Corporation, the manufacturer of the Product included...

CONFLICT OF INTEREST

The review focuses on the Helicoll® skin substitute product, manufactured by Encoll Corp. The author is a key employee of...

DATA AVAILABILITY

Not applicable for this article.

ETHICS

No ethics committee approval was required for this article type.

CONSENT

Not applicable for this article.

TRIAL REG.

Not applicable.

Crossref DOI: 10.34257/GJMRK256986


How to Cite: Gunasekaran (2026). Healing Outcomes and Cost Efficiency of Advanced Skin Substitutes for Diabetic Foot Ulcers Under the CMS Payment Framework. Global Journal of Medical Research, 26(1), 8-12. DOI: 10.34257/GJMRK256986

LICENSE

© 2026 Global Journals. Open-access article under CC BY-NC-ND 4.0 International License.

METADATA CONTINUATION

AUTHOR CONTACT QR LEDGER



FULL FUNDING STATEMENT

This study was funded by Encoll Corporation, the manufacturer of the Product included in this study. The same Company provided financial support to conduct the study and to manage the data professionally. The Company reviewed the manuscript for scientific accuracy but did not influence the interpretation of the results

FULL CONFLICT OF INTEREST STATEMENT

The review focuses on the Helicoll® skin substitute product, manufactured by Encoll Corp. The author is a key employee of Encoll Corp and has been involved in the development and commercialization of the product. This professional and financial relationship represents a potential conflict of interest. The lead author has over 40 years of experience in tissue regeneration and wound care research and commercialization.

FULL ABSTRACT

Background:

Diabetic Foot Ulcers (DFUs) are associated with substantial morbidity, health care utilization, and risk of lower-extremity amputation. Advanced wound treatments such as skin substitutes are commonly used in the management of DFUs when standard wound care alone is insufficient. Recent changes in the Medicare Physician Fee Schedule (PFS) and the Outpatient Prospective Payment System (OPPS) have standardized reimbursement for skin substitutes based on surface area applied, increasing interest in healing outcomes and treatment-related costs under the CMS payment framework.

Objective:

To descriptively compare published healing outcomes and estimated cost per healed DFU across selected advanced skin substitutes in the context of CMS payment policies.

Methods:

A descriptive comparison was conducted using published DFU healing probabilities and estimated treatment-related costs for five advanced skin substitutes: Helicoll®, Grafix®, Apligraf®, Dermagraft®, and EpiFix®. Cost per healed DFU was calculated as the ratio of estimated treatment-related cost to reported healing probability. The primary effectiveness outcome was complete ulcer healing at 12 weeks. Cost assumptions were standardized using publicly available CMS reimbursement methodologies. No probabilistic modeling or ICER-based cost-utility modeling was conducted.

Results:

Among the reported healing probabilities ranging from approximately 0.30 to 0.83 across products, Helicoll demonstrated a favorable balance of cost and effectiveness, with an annual per-patient cost of 20,000 and a reported wound closure rate of 0.83 in a 4-week clinical study with 1-week follow-up. This resulted in an estimated cost per healed DFU of approx.24,000, which was substantially lower than comparator products. Estimated treatment-related costs varied substantially, resulting in wide variation in calculated cost per healed DFU. Helicoll has the higher reported healing probabilities and the lowest calculated cost per healed DFU among evaluated products.

Conclusion:

In this comparative effectiveness analysis, Helicoll provided clinically meaningful healing outcomes at substantially lower cost compared with other specific advanced skin substitutes. These findings support Helicoll as a cost-effective treatment option for DFU management from a payer perspective and may inform reimbursement and formulary decision-making. This analysis provides a transparent cost-per-responder framework but does not constitute a formal cost-effectiveness model or systematic comparative effectiveness evaluation. Head-to-head trials and probabilistic economic modeling are required for definitive payer decision-making.

ARCHIVAL RECORD

GJMR · Vol 26 · Issue 1 · 2026

Article ID GJMR-256986 · DOI 10.34257/GJMRK256986

Print ISSN 0975-5888 · Online ISSN 2249-4618

Healing Outcomes and Cost Efficiency of Advanced Skin Substitutes for Diabetic Foot Ulcers Under the CMS Payment Framework

Subramanian Gunasekaran^{§*}

Affiliations

§ R&D, Encoll Corp., Fremont, United States

Qualifications / Designations

§ PhD

Abstract

Background: Diabetic Foot Ulcers (DFUs) are associated with substantial morbidity, health care utilization, and risk of lower-extremity amputation. Advanced wound treatments such as skin substitutes are commonly used in the management of DFUs when standard wound care alone is insufficient. Recent changes in the Medicare Physician Fee Schedule (PFS) and the Outpatient Prospective Payment System (OPPS) have standardized reimbursement for skin substitutes based on surface area applied, increasing interest in healing outcomes and treatment-related costs under the CMS payment framework.

Objective: To descriptively compare published healing outcomes and estimated cost per healed DFU across selected advanced skin substitutes in the context of CMS payment policies.

Methods: A descriptive comparison was conducted using published DFU healing probabilities and estimated treatment-related costs for five advanced skin substitutes: Helicoll®, Grafix®, Apligraf®, Dermagraft®, and EpiFix®. Cost per healed DFU was calculated as the ratio of estimated treatment-related cost to reported healing probability. The primary effectiveness outcome was complete ulcer healing at 12 weeks. Cost assumptions were standardized using publicly available CMS reimbursement methodologies. No probabilistic modeling or ICER-based cost-utility modeling was conducted.

Results: Among the reported healing probabilities ranging from approximately 0.30 to 0.83 across products, Helicoll demonstrated a favorable balance of cost and effectiveness, with an annual per-patient cost of 20,000 and a reported wound closure rate of 0.83 in a 4-week clinical study with 1-week follow-up. This resulted in an estimated cost per healed DFU of approx. 24,000, which was substantially lower than comparator products. Estimated treatment-related costs varied substantially, resulting in wide variation in calculated cost per healed DFU. Helicoll has the higher reported healing probabilities and the lowest calculated cost per healed DFU among evaluated products.

Conclusion: In this comparative effectiveness analysis, Helicoll provided clinically meaningful healing outcomes at substantially lower cost compared with other specific advanced skin substitutes. These findings support Helicoll as a cost-effective treatment option for DFU management from a payer perspective and may inform reimbursement and formulary decision-making. This analysis provides a transparent cost-per-responder framework but does not constitute a formal cost-effectiveness model or systematic comparative effectiveness evaluation. Head-to-head trials and probabilistic economic modeling are required for definitive payer decision-making.

Keywords: Diabetic Foot Ulcers, Skin Substitutes, Cost-Effectiveness, Helicoll, CMS Reimbursement, Wound Care Economics, Type I Collagen

* Corresponding Author

Subramanian Gunasekaran

DOI

10.34257/GJMRK256986

1. Introduction

Diabetic Foot Ulcers (DFUs) represent a major cause of morbidity, health care utilization, and lower-extremity amputation among patients with diabetes¹⁻³. DFUs are associated with prolonged healing, frequent clinical encounters, and increased risk of infection and hospitalization, contributing substantially to overall health care costs²⁻⁴. When standard wound care fails to achieve timely healing, advanced skin substitutes are frequently used to promote tissue regeneration and wound closure⁴⁻⁶.

In recent years, the economic evaluation of advanced skin substitutes has become increasingly complex due to significant changes in Medicare payment policy. Under 2026 Medicare Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) rules, skin substitutes are reimbursed as incident-

to supplies using standardized per-square-centimeter payment methodologies rather than product-specific pricing. These changes have shifted attention away from unit price and toward utilization patterns, surface area applied, and clinical outcomes.

Emerging clinical evidence suggests that high-purity type I collagen-based skin substitute like Helicoll, may achieve early wound area reduction and clinically meaningful healing in patients with DFUs. However, their economic value relative to established advanced skin substitutes has not been well characterized, underscoring the need for comparative effectiveness and cost-effectiveness evaluation^{1,2}.

The objective of this analysis is to descriptively compare published healing outcomes and estimated cost per healed DFU

across selected advanced skin substitutes, interpreted within CMS payment environment.

2. Methods

2.1. Study Design

This study is an exploratory cost-per-responder analysis using secondary published data⁷. It is not a systematic review, meta-analysis, or formal cost-utility model.

No AI-generated cost estimation algorithms were used in the final model. All economic inputs are explicitly defined below to ensure reproducibility. No formal PRISMA review or risk-of-bias scoring was conducted. Clinical trial number is not applicable. Therefore, cross-trial comparability is limited. Healing probabilities were extracted exactly as reported in published studies.

Because the included studies differed in study design, ulcer severity, wound size, Wagner grade, infection status, offloading methods, and standard wound-care practices, the reported healing rates could not be considered directly comparable measures of relative treatment effectiveness. Therefore, a descriptive semi-quantitative evidence weighting approach was used, taking into account factors such as study design, sample size, baseline patient comparability, endpoint definition, and follow-up duration. Accordingly, the resulting rankings should be interpreted as exploratory economic illustrations rather than definitive comparative effectiveness conclusions.

2.2. Perspective and Time Horizon

The analysis was conducted from a payer perspective intended to reflect a typical DFU treatment episode. No lifetime horizon or QALY (Quality-Adjusted Life Year) modeling was conducted.

Variable	Base Case	Low Scenario	High Scenario
Applications per episode	Product-specific average	1–2	5–8
Treated area	Product-specific average	–50%	+50%
Healing probability	Published/adjusted value	–25%	+25%
Treatment cost	Base estimate	–50%	+50%

Table 1. Sensitivity Analysis

2.6. Economic Outcome

Primary economic outcome was calculated using:

$$\text{Cost per healed ulcer} = \frac{\text{Episode cost}}{\text{Healing probability}}$$

No ICERs were calculated because:

- Cross-trial comparison violates incremental modeling assumptions
- No common comparator arm exists
- No probabilistic uncertainty modeling was performed

Dominance terminology has been removed to avoid overstating comparative claims.

2.7. Ethical Considerations

This study used aggregated, de-identified secondary data and did not involve direct patient contact. As such, institutional review board approval and patient consent were not required. The

2.3. Interventions Included

Helicoll, Grafix, Apligraf, Dermagraft, and EpiFix.

2.4. Clinical Outcome Inputs

The primary clinical outcome was complete DFU healing at approximately 12 weeks. In contrast, the early healing kinetics observed with Helicoll Skin Substitute support accelerated wound closure, achieving comparable outcomes within 5 weeks versus 12 weeks reported for other products. This efficacy was clinically demonstrated in a multicentric study⁸, which reported a wound closure probability of 0.83 at 5 weeks (4-week treatment period with 1-week follow-up).

2.5. Cost Inputs

Estimated treatment-related costs were derived from payer reimbursement information that was publicly available⁷.

Since CMS payment is applied per treated square cm, episode cost is highly sensitive to utilization assumptions, particularly number of applications and average treated wound area. A one-way sensitivity analysis is therefore necessary in future by varying the number of applications per episode across plausible real-world ranges as given in Figure ???. This analysis is essential for products requiring more frequent applications or larger treated surface areas as it may generate substantially higher episode costs even when the per-cm² reimbursement amount is standardized. Thus, future analyses should validate these inputs using independent hospital acquisition data, payer claims, chargemaster information, or registry-derived utilization costs.

analysis adhered to ethical standards for health economic research and transparent reporting.¹

3. Results

3.1. Drivers of Cost per Healed DFU

Although estimated treatment-related costs varied across products, differences in calculated cost per healed DFU were driven primarily by variation in reported healing probabilities rather than absolute cost alone. Products with similar estimated treatment-related costs demonstrated markedly different cost per healed DFU values due to differences in reported healing outcomes, as specified in Table 2. Notably, higher treatment-related cost did not consistently correspond to higher healing probability, underscoring the importance of considering both outcomes and resource use when interpreting descriptive economic metrics.

¹Helicoll[®] is a registered trademark of Encoll Corporation (Fremont, CA, USA). Grafix[®] is a registered trademark of Smith & Nephew, Inc. (Andover, MA, USA). Apligraf[®] and Dermagraft[®] are registered trademarks of Organogenesis Inc. (Canton, MA, USA). EpiFix[®] is a registered trademark of MiMedx Group, Inc. (Marietta, GA, USA). All other trademarks are the property of their respective owners.

Reported 12-week healing probabilities varied across products, ranging from approximately 0.30 to 0.83^{7,8}. Estimated treatment-related costs ranged from approximately \$20,000 to over \$33,000 per treatment episode. Helicoll demonstrated the lowest calculated cost per healed DFU among evaluated products.

Table 2. Reported Healing Outcomes and Calculated Cost per Healed DFU

Product	Estimated Treatment-Related Cost (USD)	Healing Probability	Approx. Cost per Healed DFU (USD)
Helicoll	\$20,000	0.83 at 5 weeks	\$24,000
Grafix	\$28,449	0.62 at 12 weeks	\$45,900
Apligraf	\$25,370	0.48 at 12 weeks	\$52,850
Dermagraft	\$24,552	0.38 at 12 weeks	\$64,600
EpiFix	\$33,288	0.30 at 12 weeks	\$110,960

Table Notes: (1) Reported values represent approximate 12-week healing rates as described in the cited literature⁷ and are not derived from head-to-head comparisons. Cost per healed DFU as illustrated in Figure 1 was calculated descriptively as estimated treatment-related cost divided by reported healing probability. The annual cost per patient versus 12-week healing probability is given in Figure 2. (2) The estimated treatment related cost of Helicoll was based on the respective average invoice cost. (3) The previously completed cost-analysis study used a total study duration of 12 weeks. However, owing to the accelerated healing kinetics of Helicoll, the product demonstrated substantial wound healing within 4 weeks, allowing its clinical evaluation⁸ to be completed over a shorter 4-week treatment period with 1-week follow-up (4+1 weeks). (4) The healing probabilities included in Table 2 provided healing rates that could be used for descriptive cost-per-healed-ulcer calculations and were not selectively chosen to favor any specific product. However, the available clinical trials may have differed in patient enrollment criteria, wound severity, comparator groups, and treatment protocols. (5) When multiple publications were available for a product, the study most consistent with the 12-week DFU endpoint and suitable for the cost-analysis model was selected.




Figure 1. Cost per Healed DFU (Payer Perspective). Bar chart showing the cost per healed DFU for each skin substitute. Helicoll has the lowest cost compared with other products.




Figure 2. Cost-Effectiveness Frontier for DFU Skin Substitutes. Scatter plot of annual cost per patient versus healing probability at 12 weeks for all products except Helicoll at 5 weeks. Treatments in the lower-right quadrant are more cost-effective. Helicoll shows a favorable balance, with high healing probability and the lowest annual cost.

4. Discussion

4.1. Clinical Interpretation of Descriptive Economic Metrics

From a payer perspective, lower cost per healed ulcer translates into reduced total cost of care and improved allocation of health-care resources. From a clinical standpoint, achieving timely wound closure is associated with reduced risk of infection, fewer clinic visits, and lower likelihood of amputation.

The favorable cost-effectiveness profile observed for Helicoll may be explained by its demonstrated ability to promote early wound area reduction and granulation, as reported in randomized and real-world clinical studies⁸⁻¹⁶ of high-purity type I collagen-based skin substitutes.

This study does not establish comparative clinical superiority or formal cost-effectiveness dominance. Instead, it demonstrates how cost-per-responder metrics are mathematically sensitive to healing probability inputs under CMS reimbursement standardization.

Key Interpretations:

- Cross-trial comparisons are inherently confounded by differences in patient severity, ulcer size, study design, and background standard of care.
- Without head-to-head trials or network meta-analysis, relative effectiveness cannot be conclusively determined.
- Economic rankings derived from unadjusted healing rates should not be interpreted as definitive payer guidance.

4.2. Limitations

This study is limited by reliance on secondary data and modeled assumptions rather than direct head-to-head randomized controlled trials. Real-world outcomes may vary based on patient characteristics, wound severity, and adherence to standard of care. Future prospective studies and registry-based analyses are warranted.

This analysis has several important limitations:

1. It is not a systematic review.
2. No PRISMA-compliant selection framework was implemented and no formal risk-of-bias assessment, probabilistic uncertainty analysis, and quality-adjusted life-year (QALY) modeling was conducted.
3. No adjustment for baseline ulcer size, Wagner grade, or infection status was performed.
4. Healing probabilities were drawn from separate trials with heterogeneous populations, study designs, wound characteristics, and standard-of-care procedures.

Manufacturer affiliation presents a potential conflict of interest and possible risk of selection bias in literature inclusion, cost assumptions, and interpretation of descriptive rankings.

5. The treatment-related cost inputs were obtained from public data and were not independently audited.
6. The analysis does not constitute a network meta-analysis or formal comparative effectiveness evaluation, and no common comparator arm existed across the included studies.

The findings should be interpreted as exploratory and hypothesis-generating economic illustrations rather than definitive comparative cost-effectiveness conclusions. Further validation through independent systematic reviews, registry-based real-world evidence analyses, third-party health economic modeling, and prospective head-to-head clinical trials is warranted.

5. Conclusion

This study presents a transparent cost-per-healed-ulcer framework using published 12-week healing data and standardized CMS reimbursement assumptions. In this preliminary comparative effectiveness and cost-effectiveness study, Helicoll demonstrated clinically meaningful healing outcomes at substantially lower cost compared with other advanced skin substitutes used in DFU management. It does not constitute a formal cost-effectiveness model or systematic comparative effectiveness evaluation.

Future research warrants for:

- PRISMA-compliant systematic review
- Network meta-analysis or head-to-head RCTs
- Probabilistic cost-utility modeling
- Longitudinal recurrence and amputation modeling
- Independent cost validation

■ DECLARATION

■ ACKNOWLEDGMENTS

The authors acknowledge Encoll Corp. for providing product-related cost inputs used in this analysis.

■ REFERENCES

- [1] Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. *New England Journal of Medicine*. 2017;376(24):2367–2375.
- [2] Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons N. Burden of diabetic foot ulcers for Medicare and private insurers. *Diabetes Care*. 2014;37(3):651–658.
- [3] Hicks CW, Selvarajah S, Mathioudakis N, et al. Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. *Annals of Vascular Surgery*. 2016; 33:149–58.
- [4] Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. *Advances Wound Care*. 2015;4(9):560–582.
- [5] Snyder RJ, Kirsner RS, Warriner RA, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. *Ostomy/Wound Management*. 2010;56(4):S1–24.
- [6] Game FL, Jeffcoate WJ. Dressing and Diabetic Foot Ulcers: A Current Review of the Evidence. *Plastic & Reconstructive Surgery*. 2016;138(3):S158–164.
- [7] Patel A. Cost-Effectiveness of Commonly Used Skin Substitutes in the Management of Diabetic Foot Ulcers. Poster GR-17. Presented at Symposium on Advanced Wound Care 2020.

- [8] Narayan N, Shivaiah R, Kumar V, Kumar KM, Chethan S, Gowda S. Comparative efficacy of high purity type I collagen-based skin substitute and dehydrated human amnion/chorion membrane in diabetic foot ulcers: a multicentre randomized controlled trial. *Cureus*. 2025;17(10).
- [9] Narayan N, Ramegowda YH, Raghupathi DS, Chethan S, Gowda S. Biological skin substitutes in pressure ulcers: high-purity type I collagen-based versus amnion/chorion membrane. *Cureus*. 2025;17(8).
- [10] Narayan N, Shivannaiah C, Gowda S. Evaluating the efficacy of high-purity type I collagen-based skin substitute versus dehydrated human amnion/chorion membrane in the treatment of venous leg ulcers: a randomized controlled clinical trial. *Cureus*. 2025;17(7).
- [11] Narayan N, Gowda S, Shivannaiah C. A randomized controlled clinical trial comparing the use of high purity type-I collagen-based skin substitute vs. dehydrated human amnion/chorion membrane in the treatment of diabetic foot ulcers. *Cureus*. 2024;16(12).
- [12] Gorell ES, Leung TH, Khuu P, Lane AT. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa. *Pediatric Dermatology*. 2015;32(2):220-5.
- [13] Dhanraj P. A clinical study comparing Helicoll with Scarlet Red and OpSite in the treatment of split thickness skin graft donor sites - a randomized controlled trial. *Indian Journal of Surgery*. 2013;77(Suppl 2):385-92.
- [14] Dhanraj P, Naveen N, Babu KR, Mahesh MS, Hanumanthaiah KS. Healicoll: an alternate to flap cover for bare bones and tendons. *Acta Medica International*. 2016;3(1):146-50.
- [15] Narayan N, Raghupathi D, Ramamurthy V, Chethan S, Gowda S. A comparative analysis in the treatment of full-thickness wounds: negative-pressure wound therapy (NPWT) combined with high-purity type I collagen-based skin substitute versus NPWT alone. *Cureus*. 2025;17(11).
- [16] Gunasekaran S. Clinical efficacy of type I collagen skin substitutes versus human amnion/chorion in treating diabetic foot ulcers using 55 patient randomized controlled independent two trials, one in india and the other in the USA. *Biomedical Materials & Devices*. 2026;4(1):97-104.